Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-02-11

FDA Approved: BIKTARVY — Supplemental Application (Gilead Sciences, Inc.)

View source ↗

Summary

The FDA approved a supplemental NDA for BIKTARVY from Gilead Sciences, expanding or updating its labeling and/or indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BIKTARVY (BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE)

Snippet

SUPPL AP for BIKTARVY (BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE)